Drugs / Lenvatinib
Lenvatinib
also known as
E7080 · Len · Lenvatinib mesylate · LENVIMA · E-7080 MESYLATE · ER-203492-00 · Kisplyx · Lenvanib · +6 more
Small molecule targets FGFR1, FLT1, FLT4, KDR, KIT, PDGFRA, RET via inhibition
Regulatory milestones approvals, filings & regulatory actions · 23 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed clear cell papillary renal cell carcinoma 1 milestone | |||||
| Filed | US (FDA) | LENVIMA | clear cell papillary renal cell carcinoma | 2026-02-28 | “the U.S. FDA has accepted for review two supplemental New Drug Applications for WELIREG plus LENVIMA in certain previously treated patients with advanced RCC” merck.com ↗ |
| Filed endometrial carcinoma 1 milestone | |||||
| Filed | US (FDA) | LENVIMA | endometrial carcinoma | 2019-06-17 | “Following submission on June 17, this is an accelerated approval reviewed under the FDA’s Real-Time Oncology Review (RTOR) pilot program” merck.com ↗ |
| Filed hepatocellular carcinoma 5 milestones | |||||
| Filed | Other | Lenvima | hepatocellular carcinoma | 2017-12-06 | “announced that it has submitted an application for its in-house discovered and developed anticancer agent lenvatinib mesylate (product names: Lenvima® / Kisplyx®, product name...” eisai.com ↗ “Eisai submitted applications for an additional indication for lenvatinib for the treatment of HCC in Japan (June 2017), the United States and Europe (July 2017), China (October...” eisai.com ↗ “Eisai has submitted applications for an indication covering hepatocellular carcinoma in Japan (June 2017), the United States and Europe (July 2017), China (October 2017),...” eisai.com ↗ “Eisai submitted applications for an additional indication for Lenvima for the treatment of HCC in Japan (June 2017), the United States and Europe (July 2017), and China (October 2017).” eisai.com ↗ “Eisai has submitted applications for lenvatinib for the treatment of HCC in Japan (June 2017), the United States and Europe (July 2017), China (October 2017), Taiwan (December 2017)” eisai.com ↗ “Eisai has submitted applications for an indication covering hepatocellular carcinoma in China (October 2017), Taiwan (December 2017), and other countries.” eisai.com ↗ “Eisai has submitted applications for an indication covering hepatocellular carcinoma in China (October 2017), Taiwan (December 2017) and other countries.” eisai.com ↗ “An application seeking approval of LENVIMA for use in the treatment of unresectable HCC was submitted in South Korea in March 2018.” eisai.com ↗ “Eisai has submitted applications for an indication covering hepatocellular carcinoma in Taiwan (December 2017)” eisai.com ↗ |
| Filed | China (NMPA) | Lenvima | hepatocellular carcinoma | — | “the China Food and Drug Administration (CFDA) has accepted for review a New Drug Application (NDA) submitted for Eisai's in-house discovered and developed anticancer agent...” eisai.com ↗ “Eisai submitted applications for an additional indication for lenvatinib for the treatment of HCC in Japan (June 2017), the United States and Europe (July 2017), China (October 2017)” eisai.com ↗ “Eisai has submitted applications for an indication covering hepatocellular carcinoma in Japan (June 2017), the United States and Europe (July 2017), China (October 2017)” eisai.com ↗ “Eisai has submitted applications for lenvatinib for the treatment of HCC in Japan (June 2017), the United States and Europe (July 2017), China (October 2017)” eisai.com ↗ “Eisai has submitted applications for an indication covering hepatocellular carcinoma in China (October 2017), Taiwan (December 2017), and other countries.” eisai.com ↗ “Eisai has submitted applications for an indication covering hepatocellular carcinoma in China (October 2017)” eisai.com ↗ “In China, the application of LENVIMA was submitted in October 2017” eisai.com ↗ |
| Filed | US (FDA) | Lenvima | hepatocellular carcinoma | — | “the application submitted for an additional indication of its in-house discovered and developed anticancer agent Lenvima® (generic name: lenvatinib mesylate) for the treatment...” eisai.com ↗ “Eisai submitted applications for an additional indication for lenvatinib for the treatment of HCC in Japan (June 2017), the United States and Europe (July 2017).” eisai.com ↗ “Eisai submitted applications for an additional indication for lenvatinib for the treatment of HCC in Japan (June 2017), the United States” eisai.com ↗ “Eisai has submitted applications for an indication covering hepatocellular carcinoma in Japan (June 2017), the United States” eisai.com ↗ “Eisai has submitted applications for lenvatinib for the treatment of HCC in Japan (June 2017), the United States” eisai.com ↗ |
| Filed | Japan (PMDA) | Lenvima | hepatocellular carcinoma | — | “Eisai submitted applications for an additional indication for lenvatinib for the treatment of HCC in Japan (June 2017)” eisai.com ↗ “Eisai submitted applications for an additional indication for lenvatinib for the treatment of HCC in Japan (June 2017)” eisai.com ↗ “Eisai has submitted applications for an indication covering hepatocellular carcinoma in Japan (June 2017)” eisai.com ↗ “Eisai has submitted applications for lenvatinib for the treatment of HCC in Japan (June 2017)” eisai.com ↗ |
| Filed | EU (EMA) | Lenvima | hepatocellular carcinoma | — | “Eisai submitted applications for an additional indication for lenvatinib for the treatment of HCC in Japan (June 2017), the United States and Europe (July 2017).” eisai.com ↗ “Eisai submitted applications for an additional indication for lenvatinib for the treatment of HCC in Japan (June 2017), the United States and Europe (July 2017)” eisai.com ↗ “Eisai has submitted applications for an indication covering hepatocellular carcinoma in Japan (June 2017), the United States and Europe (July 2017)” eisai.com ↗ “Eisai has submitted applications for lenvatinib for the treatment of HCC in Japan (June 2017), the United States and Europe (July 2017)” eisai.com ↗ “Eisai has submitted applications for an indication covering hepatocellular carcinoma in Europe (July 2017)” eisai.com ↗ |
| Filed renal cell adenocarcinoma 3 milestones | |||||
| Filed | Japan (PMDA) | LENVIMA | renal cell adenocarcinoma | 2026-03-27 | “an application for LENVIMA ® (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, has been submitted in Japan” eisai.com ↗ |
| Filed | EU (EMA) | — | renal cell adenocarcinoma | 2016-01-12 | “has submitted a new application to the European Medicines Agency (EMA) for its in-house developed novel anticancer agent lenvatinib mesylate” eisai.com ↗ |
| Filed | US (FDA) | LENVIMA | renal cell adenocarcinoma | — | “FDA accepted supplemental applications for WELIREG plus Lenvima in certain previously treated patients with advanced RCC, based on the Phase 3 LITESPARK-011 trial” merck.com ↗ “FDA has accepted two supplemental New Drug Applications (sNDA) for review based on Phase 3 LITESPARK-011 trial evaluating WELIREG in combination with LENVIMA” eisai.com ↗ |
| Filed thymic mucoepidermoid carcinoma 1 milestone | |||||
| Filed | Japan (PMDA) | LENVIMA | thymic mucoepidermoid carcinoma | 2020-07-30 | “Eisai has submitted an application in Japan for the additional indication of treatment of unresectable thymic carcinoma for multiple receptor tyrosine kinase inhibitor LENVIMA” eisai.com ↗ |
| Filed thyroid cancer, nonmedullary, 1 1 milestone | |||||
| Filed | Japan (PMDA) | — | thyroid cancer, nonmedullary, 1 | 2014-06-26 | “has submitted its first marketing authorization application for its novel in-house developed anticancer agent lenvatinib mesylate (“lenvatinib”) for the treatment of thyroid...” eisai.com ↗ “An application seeking marketing approval of lenvatinib for the indication of thyroid cancer was submitted in Japan on June 26, 2014.” eisai.com ↗ “the first application for marketing authorization of lenvatinib in the world was submitted in Japan in June 2014.” eisai.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Label expansions (9) | US (FDA) | LENVIMA | — | 2016-05-13 – 2025-01-29 | fda.gov ↗ |
| Approved | EU (EMA) | Lenvima | — | 2015-05-28 | europa.eu ↗ |
| Approved | US (FDA) | LENVIMA | — | 2015-02-13 | fda.gov ↗ |
Trials 508 · started per year
today
US approved 2015
EU approved 2015
2
1
1
3
8
8
1
1
2
7
12
13
24
35
43
66
64
65
54
47
50
200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 09 trials | ||||||
| Phase 0 | NCT07356466 | May 2025 → Apr 2027 expected | gastric cancer | Fujian Medical University | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT05553782 | Nov 2023 → Apr 2029 expected | head and neck squamous cell carcinoma, salivary gland adenoid cystic carcinoma | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT05733715 | May 2023 → Jun 2026 overdue | renal cell carcinoma | Abramson Cancer Center at Penn Medicine | Recruiting | No outcome recorded |
| Phase 0 | NCT06321120 | Mar 2023 → Apr 2024 | — | Hadassah Medical Organization | Unknown | No outcome recorded |
| Phase 0 | NCT05188118 | Feb 2023 → Feb 2025 | renal cell carcinoma | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 0 | NCT05411757 | Jun 2022 → Jun 2023 | liver cancer | Shandong Public Health Clinical Center | Unknown | No outcome recorded |
| Phase 0 | NCT05041153 | Feb 2022 → Dec 2026 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05131698 | Mar 2021 → Dec 2023 | hepatocellular carcinoma | Cancer Hospital of Guangxi Medical University | Unknown | No outcome recorded |
| Phase 0 | NCT04974281 | Jan 2021 → Dec 2022 | hepatocellular carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 145 trials | ||||||
| Phase 1 | NCT06161558 | Jul 2025 | neoplasm | National Cancer Institute (NCI) | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT06462183 | Aug 2024 → Dec 2027 expected | adenoid cystic carcinoma, colorectal cancer | Rgenta Therapeutics Inc | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06470256 | Jun 2024 → Jun 2027 expected | hepatocellular carcinoma | Zhiyong Huang | Recruiting | No outcome recorded |
| Phase 1 | NCT06463444 | Jun 2024 → Jun 2025 | hepatocellular carcinoma | Chen Xiaoping | Unknown | No outcome recorded |
| Phase 1 | NCT05803928 | Jan → Nov 2024 overdue | hepatocellular carcinoma | Hua Li | Recruiting | No outcome recorded |
| Phase 1 | NCT05767684 | Jun 2023 → Mar 2025 | refractory malignant neoplasm | National Health Research Institutes, Taiwan | Unknown | No outcome recorded |
| Phase 1 | NCT05603910 | Apr 2023 → Apr 2027 expected | endometrial carcinoma | Aaron Wolfson | Recruiting | No outcome recorded |
| Phase 1 | NCT05675462 | Mar 2023 → Dec 2025 | hepatocellular carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 1 | NCT05225116 | Jan 2023 → Dec 2025 | hepatocellular carcinoma | Beijing Tsinghua Chang Gung Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT05533892 | Sep 2022 → Aug 2024 | hepatocellular carcinoma | Wan-Guang Zhang | Unknown | No outcome recorded |
| Phase 1 | NCT05273554 | Aug 2022 → Sep 2026 | adenocarcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT05303090 | Mar 2022 → Apr 2024 | pancreatic ductal adenocarcinoma | Fudan University | Completed | No outcome recorded |
| Phase 1 | NCT05155189 | Feb 2022 → May 2026 overdue | hepatocellular carcinoma | Zhejiang University | Recruiting | No outcome recorded |
| Phase 1 | NCT05171530 | Jan → Dec 2022 | carcinoma | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT05081180 | Dec 2021 → Feb 2026 overdue | central nervous system neoplasm | EMD Serono Research & Development Institute, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05221775 | Nov 2021 → Mar 2023 | gastric carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT05030506 | Oct 2021 → Jun 2027 expected | renal cell carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04422899 | Aug 2020 → Sep 2021 | wet macular degeneration | AiViva BioPharma, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04427293 | Jul 2020 → Jul 2026 overdue | triple-negative breast carcinoma | University of Illinois at Chicago | Recruiting | No outcome recorded |
| Phase 1 | NCT03878524 | Apr → Dec 2020 | acute myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, castration-resistant prostate carcinoma +14 | OHSU Knight Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03324373 | Mar 2019 → Sep 2023 | renal cell carcinoma | Yousef Zakharia | Completed | No outcome recorded |
| Phase 1 | NCT03009292 | Aug → Dec 2018 | cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03524326 | Apr 2018 → Oct 2022 | head and neck squamous cell carcinoma, skin squamous cell carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT03418922 | Jan 2018 → Dec 2022 | hepatocellular carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03006926 | Feb 2017 → Oct 2019 | hepatocellular carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03006887 | Jan 2017 → Apr 2020 | cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02915172 | Dec 2016 → Dec 2022 | bone cancer, breast cancer, cancer of unknown primary site, central nervous system cancer +8 | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT02935309 | Oct 2016 → Oct 2019 | rectum adenocarcinoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT02953743 | Sep 2016 → Jun 2017 | hepatocellular carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02788708 | May 2016 → Dec 2021 | endometrial cancer, fallopian tube carcinoma, ovarian cancer, primary peritoneal carcinoma | Floor Backes | Completed | No outcome recorded |
| Phase 1 | NCT02686164 | Apr 2016 → Jan 2017 | neoplasm | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02454478 | Jul 2015 → May 2017 | renal cell carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02792829 | Aug 2014 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02199379 | Nov 2011 → Oct 2012 | impaired renal function disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02199392 | Nov 2011 → Jan 2012 | phosphoglycoprotein 1 | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02421042 | Jun 2011 → Jul 2012 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02198170 | Feb → Jun 2011 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01268293 | Feb → Dec 2011 | cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01525394 | Dec 2010 → Aug 2011 | lymphoma, refractory malignant neoplasm | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01240408 | Jul 2010 → Nov 2011 | cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02578316 | Jun 2009 → Jun 2010 | cancer, lymphoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00832819 | Feb 2009 → Jul 2011 | non-small cell lung carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00280397 | Jan 2006 → Sep 2008 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00121719 | Jul 2005 → Jun 2009 | lymphoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00121680 | Jul 2005 → Sep 2011 | metastatic melanoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/250 trials · 1 met primary · 1 missed | ||||||
| Phase 1/2 | NCT07540832 | Sep 2026 → Sep 2028 expected | hepatocellular carcinoma | Zhejiang Haichang Biotech Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07683949 | Jun 2026 → Oct 2029 expected | colorectal cancer | Seoul National University Bundang Hospital | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT07636798 | Jun 2026 → Mar 2029 expected | biliary tract cancer | West China Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07482059 | Feb → Jun 2026 overdue | hepatocellular carcinoma | West China Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07149090 | Nov 2025 → Jul 2027 expected | gastric adenocarcinoma | Asan Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07096609 | Oct 2025 → Dec 2027 expected | gastrointestinal stromal tumor | Asan Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07282184 | Oct 2025 → Jun 2027 expected | hepatocellular carcinoma | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06682780 | Sep 2025 → Dec 2028 expected | neoplasm | LaNova Medicines Limited | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06409637 | Jan 2025 → Dec 2027 expected | hepatocellular carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06746961 | Jan 2025 → Jul 2026 overdue | esophageal squamous cell carcinoma | The First Affiliated Hospital of Zhengzhou University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05901194 | Jul 2024 → Apr 2027 expected | hepatocellular carcinoma | Assistance Publique - Hôpitaux de Paris | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05973903 | Jun 2024 → Oct 2026 | glioblastoma | Tel Aviv Medical Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT06253494 | May 2024 → Dec 2026 expected | endometrial carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06110793 | Dec 2023 → Nov 2027 expected | breast cancer | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06140576 | Nov 2023 → Dec 2025 overdue | breast neoplasm | Zhejiang Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05797805 | Sep 2023 → May 2026 overdue | hepatocellular carcinoma | Iterion Therapeutics | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05319730 | May 2023 → Jun 2027 expected | esophageal squamous cell carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05286320 | Mar 2023 → Sep 2026 overdue | hepatocellular carcinoma | National Taiwan University Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06040177 | Feb 2023 | hepatocellular carcinoma, portal vein thrombosis | First Affiliated Hospital of Guangxi Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05842317 | Sep 2022 → Apr 2024 | hepatocellular carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT05342636 | Jul 2022 → Dec 2025 | esophageal squamous cell carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT04911959 | Jul 2022 → Jun 2024 | hepatocellular carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05740215 | May 2022 → May 2024 | cancer | Shandong New Time Pharmaceutical Co., LTD | Unknown | No outcome recorded |
| Phase 1/2 | NCT05327582 | Apr 2022 → Apr 2023 | biliary tract cancer, malignant pancreatic neoplasm | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT05262413 | Feb 2022 → Jul 2023 | renal cell carcinoma | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05024214 | Nov 2021 → Dec 2026 expected | hepatocellular carcinoma, non-small cell lung carcinoma, renal cell carcinoma | 3D Medicines (Sichuan) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05091346 | Oct 2021 → Oct 2024 | colorectal neoplasm, hepatocellular carcinoma, melanoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT05042336 | Sep 2021 → Jun 2023 | digestive system neoplasm | Sichuan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04938817 | Aug 2021 → Dec 2029 expected | small cell lung carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04700072 | May 2021 → Oct 2025 | melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT04626518 | Dec 2020 → Jul 2026 | clear cell renal carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT04626479 | Dec 2020 → Aug 2026 | renal cell carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT04997850 | Oct 2020 → May 2022 | hepatocellular carcinoma | Xinrui Zhu，MD | Completed | No outcome recorded |
| Phase 1/2 | NCT04443309 | Sep 2020 → Aug 2024 | hepatocellular carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04300556 | Aug 2020 → Aug 2030 expected | cancer | Eisai Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04444167 | Jul 2020 → Nov 2023 | hepatocellular carcinoma | Akeso | Completed | No outcome recorded |
| Phase 1/2 | NCT04305054 | Jul 2020 → May 2026 | melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT04305041 | Jun 2020 → Aug 2025 | melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT04008797 | Jul 2019 → Mar 2027 expected | colorectal cancer, endometrial cancer, hepatocellular carcinoma | Eisai Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03526679 | Jul 2018 → Jun 2021 | leiomyosarcoma, liposarcoma | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT03245151 | Nov 2017 → Sep 2022 | refractory malignant neoplasm | Eisai Inc. | Completed | Mixed |
| Phase 1/2 | NCT02861573 | Nov 2016 → Oct 2027 expected | castration-resistant prostate carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02562118 | Oct 2015 → Jan 2027 expected | breast cancer | National University Hospital, Singapore | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02501096 | Jul 2015 → Aug 2020 | neoplasm | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02432274 | Dec 2014 → Jul 2019 | differentiated thyroid carcinoma, osteosarcoma | Eisai Inc. | Completed | Missed primary |
| Phase 1/2 | NCT01433991 | Oct 2011 → Mar 2015 | cancer | Eisai Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT01136733 | Aug 2010 → Jun 2014 | renal cell carcinoma | Eisai Inc. | Completed | Met primary |
| Phase 1/2 | NCT01133977 | Apr 2010 → Jun 2014 | melanoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01133756 | Mar 2010 → Feb 2012 | ovarian cancer | Eisai Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00946153 | Jul 2009 → Jun 2014 | hepatocellular carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 2301 trials · 8 met primary · 4 missed | ||||||
| Phase 2 | NCT07256223 | Dec 2026 → Nov 2027 expected | clear cell renal carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07843901 | Nov 2026 → Aug 2028 expected | parathyroid gland carcinoma | Yonsei University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07847359 | Oct 2026 → Dec 2028 expected | cutaneous melanoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07776080 | Oct 2026 → Oct 2027 expected | hepatocellular carcinoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 2 | NCT07827807 | Sep 2026 → May 2029 expected | hepatocellular carcinoma | Chang Gung Memorial Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07680088 | Sep 2026 → Sep 2028 expected | anal squamous cell carcinoma | University of Texas Southwestern Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07829874 | Sep 2026 → Sep 2028 expected | biliary tract cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07801287 | Sep 2026 → Aug 2028 expected | hepatocellular carcinoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07594015 | Aug 2026 → Aug 2031 expected | endometrial cancer | University of Miami | Recruiting | No outcome recorded |
| Phase 2 | NCT07686926 | Aug 2026 → Jul 2028 expected | esophageal squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Show all 301 trials opens the full record — a long page | ||||||
| Phase 2/39 trials · 1 met primary | ||||||
| Phase 2/3 | NCT07177716 | Oct 2025 → Dec 2028 expected | cervical cancer | L & L Bio Co., Ltd., Ningbo, China | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05250843 | May 2022 → Dec 2023 | hepatocellular carcinoma | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05322187 | Apr 2022 → Sep 2023 | childhood malignant neoplasm, hepatoblastoma, transitional cell neoplasm | RenJi Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT05001724 | Oct 2021 → Feb 2023 | non-small cell lung carcinoma | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Terminated | No outcome recorded |
| Phase 2/3 | NCT04669496 | Jan 2021 → Apr 2025 overdue | intrahepatic cholangiocarcinoma | Shanghai Zhongshan Hospital | Active not recruiting | Met primary |
| Phase 2/3 | NCT04909866 | Jan 2021 → Sep 2022 | hepatocellular carcinoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 2/3 | NCT04319484 | May 2020 → Jan 2025 | hepatocellular carcinoma, portal vein thrombosis | RenJi Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT04168944 | Nov 2019 → Sep 2022 | hepatocellular carcinoma | RenJi Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT04044651 | Oct 2019 → Mar 2021 | hepatocellular carcinoma | Shi Ming | Withdrawn | No outcome recorded |
| Phase 352 trials · 6 met primary · 11 missed | ||||||
| Phase 3 | NCT07809256 | Sep 2026 → Aug 2028 expected | non-small cell lung carcinoma | EuroCityClinic LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT07691515 | Jul 2026 → Jan 2030 expected | intrahepatic cholangiocarcinoma | Zhejiang Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07537946 | May 2026 → May 2031 expected | hepatocellular carcinoma, metastatic neoplasm | Tongji Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07475026 | May 2026 → Jan 2030 expected | hepatocellular carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06841172 | Jul 2025 → Jul 2027 expected | hepatocellular carcinoma | Shandong Cancer Hospital and Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT06371157 | Aug 2024 → Oct 2025 overdue | hepatocellular carcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 3 | NCT06492395 | Aug 2024 → Jul 2026 overdue | hepatocellular carcinoma | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT06364631 | Apr 2024 → May 2032 expected | clear cell renal carcinoma | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT05910970 | Feb 2024 → Dec 2025 | hepatocellular carcinoma | Guangxi Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT06089382 | Nov 2023 → Nov 2024 overdue | hepatocellular carcinoma | Tongji Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06041477 | Oct 2023 → Jul 2027 expected | chemotherapy-induced toxicity, hepatocellular carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05823311 | Sep 2023 → Dec 2026 expected | cholangiocarcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 3 | NCT05985798 | Aug 2023 → Jul 2027 expected | hepatocellular carcinoma | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT05342194 | Jun 2023 → May 2027 expected | intrahepatic cholangiocarcinoma | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05718232 | Mar 2023 → Feb 2027 expected | hepatocellular carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05608200 | Nov 2022 → Oct 2026 expected | hepatocellular carcinoma | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT05220020 | May 2022 → Feb 2024 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT05301842 | Mar 2022 → Feb 2026 overdue | hepatocellular carcinoma | AstraZeneca | Active not recruiting | Met primary |
| Phase 3 | NCT05056337 | Aug 2021 → Nov 2023 | hepatocellular carcinoma | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04949256 | Jul 2021 → May 2025 | esophageal squamous cell carcinoma | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT04770896 | Apr 2021 → Jun 2026 overdue | hepatocellular carcinoma | Hoffmann-La Roche | Active not recruiting | Missed primary |
| Phase 3 | NCT04736706 | Apr 2021 → Feb 2026 overdue | clear cell renal carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | Missed primary |
| Phase 3 | NCT04776148 | Mar 2021 → Sep 2024 | colorectal neoplasm | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT04586231 | Feb 2021 → Feb 2026 overdue | renal cell carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | Mixed |
| Phase 3 | NCT04229355 | Feb 2021 → Dec 2022 | hepatocellular carcinoma | Guangxi Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT04662710 | Dec 2020 → Oct 2024 | gastroesophageal adenocarcinoma | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 3 | NCT05523323 | Oct 2020 → Aug 2023 | head and neck squamous cell carcinoma | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 3 | NCT04889118 | Jul 2020 → Jan 2023 | melanoma | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 3 | NCT04246177 | May 2020 → Aug 2025 | hepatocellular carcinoma | Merck Sharp & Dohme LLC | Terminated | Mixed Stop: Business |
| Phase 3 | NCT04237740 | May 2020 → Jan 2022 | hepatocellular carcinoma | RenJi Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04199104 | Feb 2020 → May 2023 | head and neck squamous cell carcinoma | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 3 | NCT04164199 | Dec 2019 → May 2026 | cancer | BeOne Medicines | Completed | No outcome recorded |
| Phase 3 | NCT04716933 | Nov 2019 → Aug 2023 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 3 | NCT04676412 | Oct 2019 → May 2021 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT04865289 | Oct 2019 → Oct 2023 | endometrial carcinoma | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT03976375 | Jun 2019 → Aug 2023 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT03905967 | Jun 2019 → Apr 2023 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | Met primary |
| Phase 3 | NCT03898180 | May 2019 → Jul 2021 | urothelial carcinoma | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT03744247 | Apr 2019 → Jan 2021 | hepatocellular carcinoma | Sun Yat-sen University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03884101 | Apr 2019 → Oct 2023 | endometrium neoplasm | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT03829319 | Mar 2019 → Aug 2023 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT03829332 | Mar 2019 → May 2021 | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 3 | NCT03820986 | Mar 2019 → Jan 2023 | melanoma | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 3 | NCT03791918 | Jan 2019 → Jan 2022 | hepatocellular carcinoma | Sun Yat-sen University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT03713593 | Dec 2018 → Jun 2022 | hepatocellular carcinoma | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT03775395 | Dec 2018 → Dec 2021 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT03486873 | Aug 2018 → Aug 2043 expected | cancer, hematopoietic and lymphoid cell neoplasm | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT03517449 | Jun 2018 → Mar 2022 | endometrial cancer | Eisai Inc. | Completed | Met primary |
| Phase 3 | NCT04053972 | Jan 2018 → Dec 2022 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT02966093 | Jan 2017 → Jul 2019 | differentiated thyroid carcinoma | Eisai Inc. | Completed | Met primary |
| Phase 3 | NCT02811861 | Oct 2016 → Aug 2020 overdue | renal cell carcinoma | Eisai Inc. | Active not recruiting | Met primary |
| Phase 3 | NCT01321554 | Mar 2011 → Nov 2013 | thyroid cancer | Eisai Inc. | Completed | Met primary |
| Phase 411 trials | ||||||
| Phase 4 | NCT07160361 | Oct 2025 → Dec 2028 expected | hepatocellular carcinoma | Second Affiliated Hospital of Xi'an Jiaotong University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07010393 | Jul 2025 → Dec 2027 expected | thyroid tumor | Fujian Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06499610 | Jul 2024 → Oct 2027 expected | gastric cancer | First Affiliated Hospital Xi'an Jiaotong University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06417606 | May 2024 → Apr 2025 | intrahepatic cholangiocarcinoma | Zhiyong Huang | Unknown | No outcome recorded |
| Phase 4 | NCT06311916 | May 2024 → Dec 2027 expected | hepatocellular carcinoma | Chen Xiaoping | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06311929 | Apr 2024 → Dec 2027 expected | hepatocellular carcinoma | Chen Xiaoping | Recruiting | No outcome recorded |
| Phase 4 | NCT06003673 | Jul 2023 → Jul 2024 | hepatocellular carcinoma | First Affiliated Hospital of Fujian Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT04297254 | Feb 2021 → Jul 2023 | hepatocellular carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT06195228 | Jan 2020 → Dec 2026 expected | — | Fudan University | Recruiting | No outcome recorded |
| Phase 4 | NCT04127396 | Sep 2019 → Aug 2021 | hepatocellular carcinoma, portal vein thrombosis | Beijing Ditan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03573960 | Apr 2018 → Sep 2025 | thyroid cancer | Eisai Inc. | Completed | No outcome recorded |
| Phase not applicable29 trials | ||||||
| — | NCT07535840 | May → Dec 2026 expected | hepatocellular carcinoma | Tongji Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07480382 | Apr 2026 → Dec 2027 expected | hepatocellular carcinoma | Hong Wu | Not yet recruiting | No outcome recorded |
| — | NCT07077798 | Aug 2025 → Aug 2026 overdue | hepatocellular carcinoma | Wan-Guang Zhang | Not yet recruiting | No outcome recorded |
| — | NCT07188311 | Apr 2025 → Apr 2027 expected | childhood malignant neoplasm, hepatoblastoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| — | NCT07408804 | Apr 2025 → Sep 2026 overdue | hepatocellular carcinoma | Bangladesh Medical University | Recruiting | No outcome recorded |
| — | NCT06740370 | Dec 2024 → Dec 2025 overdue | hepatocellular carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| — | NCT06609850 | Oct 2024 → Oct 2026 expected | hepatocellular carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| — | NCT06622031 | Oct 2024 → Dec 2026 expected | hepatocellular carcinoma, portal vein thrombosis | Sun Yat-sen University | Recruiting | No outcome recorded |
| — | NCT06519721 | Aug 2024 → Dec 2025 overdue | hepatocellular carcinoma | RenJi Hospital | Active not recruiting | No outcome recorded |
| — | NCT06463548 | Jul 2024 → Dec 2025 overdue | biliary tract cancer | Yunpeng Liu | Not yet recruiting | No outcome recorded |
| — | NCT06061276 | May 2024 → Jun 2025 overdue | hepatocellular carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| — | NCT06070636 | May 2024 → Jan 2025 overdue | hepatocellular carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| — | NCT05718882 | Aug 2023 → Apr 2024 | hepatocellular carcinoma, refractory malignant neoplasm | RenJi Hospital | Terminated | No outcome recorded |
| — | NCT06277024 | Jan 2023 → Dec 2024 overdue | — | Fujian Medical University | Recruiting | No outcome recorded |
| — | NCT05621499 | Nov 2022 → Nov 2023 | hepatocellular carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| — | NCT05444478 | Jul 2022 → Jul 2025 overdue | hepatocellular carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| — | NCT05339581 | May 2022 → Dec 2023 | hepatocellular carcinoma, portal vein thrombosis | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT05247996 | Mar → Dec 2022 | intrahepatic cholangiocarcinoma | The Central Hospital of Lishui City | Unknown | No outcome recorded |
| — | NCT05215665 | Jan 2022 → May 2024 | cholangiocarcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| — | NCT05391867 | Jan → Dec 2022 | hepatocellular carcinoma | Sir Salimullah Medical College Mitford Hospital | Unknown | No outcome recorded |
| — | NCT05162898 | Jan 2022 → Dec 2023 | hepatocellular carcinoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| — | NCT05277675 | Nov 2021 → Nov 2022 | hepatocellular carcinoma | Southwest Hospital, China | Unknown | No outcome recorded |
| — | NCT04618367 | Jan → Dec 2021 | hepatocellular carcinoma, portal vein thrombosis | Sun Yat-sen University | Completed | No outcome recorded |
| — | NCT04642547 | Dec 2020 → Mar 2023 | hepatocellular carcinoma | RenJi Hospital | Completed | No outcome recorded |
| — | NCT04443322 | Sep 2020 → Dec 2021 | hepatocellular carcinoma | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT04444193 | Aug 2020 → May 2021 | endometrial cancer | Shanghai First Maternity and Infant Hospital | Unknown | No outcome recorded |
| — | NCT04425226 | Aug 2020 → Dec 2022 | hepatocellular carcinoma | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT07537985 | Jan 2020 → Aug 2025 | hepatocellular carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| — | NCT05592197 | Oct 2018 → Mar 2023 | hepatocellular carcinoma | Sun Yat-sen University | Withdrawn | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT03533361 | — | thyroid cancer | Eisai Inc. | Approved for marketing | No outcome recorded |
| — | NCT02211222 | ? → Aug 2015 | differentiated thyroid carcinoma | Eisai Inc. | Approved for marketing | No outcome recorded |
| Comparator or background therapy68 trials | ||||||
| Phase 0 | NCT05007587 Background | Jul 2021 → Jun 2022 | hepatocellular carcinoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT06327269 Comparator | Apr 2021 → Dec 2024 overdue | — | Chang Gung Memorial Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06858813 Comparator | Apr 2025 → Sep 2030 expected | hepatocellular carcinoma, non-small cell squamous lung carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 1 | NCT06363006 Background | Mar 2024 → Jan 2026 overdue | hepatocellular carcinoma | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT04522323 Background | Aug 2020 → Sep 2025 overdue | renal cell carcinoma | MedImmune LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03564691 Background | Jul 2018 → Sep 2025 | neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT02720068 Background | May 2016 → Mar 2024 | neoplasm | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT07282509 Background | Dec 2025 → Jun 2028 expected | hepatocellular carcinoma | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07269158 Comparator | Dec 2025 → Sep 2029 expected | biliary tract neoplasm | Yonsei University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07097935 Background | Jul 2025 → Jul 2027 expected | clear cell renal carcinoma | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06896396 Background | Apr 2025 → Jun 2027 expected | hepatocellular carcinoma | Zhiyong Huang | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05774899 Background | Jun 2023 → Jun 2027 expected | adenoid cystic carcinoma | Michael J. Dennis, MD | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05620134 Background | Oct 2022 → Oct 2025 overdue | clear cell renal carcinoma, colorectal adenocarcinoma, gastric adenocarcinoma, gastroesophageal cancer +13 | Salubris Biotherapeutics Inc | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04977453 Background | Aug 2021 → Jun 2028 expected | cervical cancer, clear cell renal carcinoma, metastatic neoplasm, non-small cell squamous lung carcinoma +1 | GI Innovation, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03867370 Comparator | Apr 2019 → Aug 2023 | hepatocellular carcinoma | Shanghai Junshi Bioscience Co., Ltd. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03781934 Background | Sep 2018 → Jan 2025 | hepatocellular carcinoma, intrahepatic cholangiocarcinoma | Medivir | Completed | No outcome recorded |
| Phase 2 | NCT07829926 Background | Nov 2026 expected | hepatocellular carcinoma | First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05106127 Background | Aug 2026 → Mar 2027 expected | endometrial cancer | Evergreen Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07550972 Comparator | May 2026 → Mar 2030 expected | head and neck squamous cell carcinoma | Zhejiang Provincial People's Hospital | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT07219459 Background | Mar 2026 → Sep 2029 expected | hepatocellular carcinoma | CatalYm GmbH | Recruiting | No outcome recorded |
| Phase 2 | NCT07412054 Background | Mar 2026 → Jun 2027 expected | hepatocellular carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07328009 Comparator | Jan 2026 → Jan 2029 expected | hepatocellular carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT07150377 Background | Aug 2025 → Aug 2026 overdue | hepatocellular carcinoma | The Second Affiliated Hospital of Shandong First Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07099274 Background | Aug 2025 → Dec 2027 expected | hepatocellular carcinoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06984718 Comparator | Jun 2025 → Nov 2026 expected | hepatocellular carcinoma | Akeso | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06892925 Background | Jun 2025 → Apr 2026 overdue | biliary tract cancer | Eastern Hepatobiliary Surgery Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07832006 Background | Apr 2025 → Dec 2028 expected | hepatocellular carcinoma | Shunda Du | Recruiting | No outcome recorded |
| Phase 2 | NCT06904183 Background | Apr 2025 → Mar 2029 expected | hepatocellular carcinoma | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06904196 Comparator | Apr 2025 → Mar 2028 expected | hepatocellular carcinoma | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06592612 Comparator | Oct 2024 → Oct 2026 expected | hepatocellular carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06563934 Background | Aug 2024 → May 2026 overdue | liver cancer | Xu Yong, MD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05822752 Comparator | Sep 2023 → Nov 2026 expected | hepatocellular carcinoma | AbbVie | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07304388 Comparator | Feb 2023 → Apr 2025 | intrahepatic cholangiocarcinoma | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 2 | NCT05673824 Background | Jan 2023 → Sep 2025 | poisoning | Fudan University | Completed | No outcome recorded |
| Phase 2 | NCT05185739 Comparator | Aug 2022 → Jul 2028 expected | hepatocellular carcinoma | University College, London | Recruiting | No outcome recorded |
| Phase 2 | NCT05166239 Background | Jan 2022 → Dec 2023 | hepatocellular carcinoma, portal vein thrombosis | Peking University | Completed | No outcome recorded |
| Phase 2 | NCT05007106 Background | Sep 2021 → Aug 2025 | cholangiocarcinoma, endometrium neoplasm, gallbladder neoplasm, gastric neoplasm +7 | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT04777084 Background | Aug 2021 → Dec 2024 overdue | non-small cell lung carcinoma | Hunan Province Tumor Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05582278 Background | Jan 2021 → Jan 2024 | hepatocellular carcinoma | Wen Li | Unknown | No outcome recorded |
| Phase 2 | NCT04428151 Comparator | Aug 2020 → May 2024 | head and neck squamous cell carcinoma | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 2 | NCT04203901 Background | Jul 2020 → Sep 2023 | renal cell carcinoma | CoImmune | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04154189 Comparator | Mar 2020 → Jun 2022 | osteosarcoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04361331 Background | Mar 2020 → Sep 2023 | intrahepatic cholangiocarcinoma | Shanghai Zhongshan Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03803254 Background | Jan 2019 → Jan 2021 | hepatocellular carcinoma | Sun Yat-sen University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT05033522 Comparator | Aug 2023 → Nov 2026 | hepatocellular carcinoma | Mirror Biologics, Inc. | Suspended | No outcome recorded Stop: Business |
| Phase 2/3 | NCT05408221 Background | Nov 2022 → Aug 2025 overdue | hepatocellular carcinoma | Shandong New Time Pharmaceutical Co., LTD | Recruiting | No outcome recorded |
| Phase 3 | NCT05077215 Background | Dec 2026 → Dec 2027 expected | endometrial cancer | Evergreen Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07836530 Comparator | Oct 2026 → Sep 2029 expected | hepatocellular carcinoma | BeOne Medicines | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07383441 Background | Jun 2026 → Jan 2033 expected | clear cell renal carcinoma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 3 | NCT07405164 Background | Mar 2026 → Apr 2034 expected | cancer, von Hippel-Lindau disease | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06726421 Background | Sep 2024 → Sep 2030 expected | renal cell carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05738616 Background | May 2024 → May 2027 expected | hepatocellular carcinoma | Wen Tianfu | Recruiting | No outcome recorded |
| Phase 3 | NCT06201065 Background | Dec 2023 → Jul 2025 overdue | hepatocellular carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05608213 Comparator | Nov 2022 → Oct 2026 expected | hepatocellular carcinoma | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 3 | NCT05899049 Background | Jul 2022 → Jun 2027 expected | clear cell renal carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04687163 Background | Dec 2020 → Dec 2022 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT04523493 Background | Jun 2020 → Dec 2026 expected | hepatocellular carcinoma | Shanghai Junshi Bioscience Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04194775 Comparator | Dec 2019 → Jun 2025 overdue | hepatocellular carcinoma | CStone Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04039607 Comparator | Sep 2019 → Jul 2026 overdue | hepatocellular carcinoma | Bristol-Myers Squibb | Active not recruiting | Met primary |
| Phase 3 | NCT04053985 Comparator | Jan 2018 → Dec 2022 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 3 | NCT01761266 Comparator | Mar 2013 → Nov 2016 | hepatocellular carcinoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT06903312 Comparator | Jun 2025 → Oct 2027 expected | renal cell carcinoma | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Recruiting | No outcome recorded |
| Phase 4 | NCT05949424 Comparator | May 2024 → Mar 2025 | breast carcinoma, endometrial carcinoma, ovarian carcinoma, renal cell carcinoma +1 | University Medical Center Groningen | Unknown | No outcome recorded |
| Phase 4 | NCT06311942 Background | Apr 2024 → Dec 2027 expected | hepatocellular carcinoma | Chen Xiaoping | Recruiting | No outcome recorded |
| — | NCT07208526 Comparator | Dec 2025 → Jun 2028 expected | intrahepatic cholangiocarcinoma | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT04443049 Background | Jul 2020 → Jun 2022 | cirrhosis of liver, hepatocellular carcinoma | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| — | NCT03838796 Comparator | Jan 2019 → Jun 2022 | hepatocellular carcinoma | Fudan University | Unknown | No outcome recorded |
| — | NCT02592356 Background | Nov 2015 → Mar 2024 | malignant adrenal gland pheochromocytoma, medullary thyroid gland carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 178
All press releases naming this drug 231 releases
| Date | Issuer | Release |
|---|---|---|
| Show all 231 releases opens the full record — a long page | ||
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 582 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lenvatinib | “IBI318, 300 mg, administered by intravenous infusion on the first day of each cycle, 1 cycle every 2 weeks (Q2W), continuous medication; lenvatinib 8 mg, orally, continued...” NCT04777084 ↗569“Taken together, we hypothesize that combining pembrolizumab with lenvatinib in metastatic UM may target essential cellular oncogenic pathways while normalizing tumor...” NCT05282901 ↗ “Drugs may include all or a subset of the following which each may be tested as single agents or in any number of combinations including, but not limited to: Lenvatinib,...” NCT05553782 ↗ “Successful organoids undergo drug sensitivity testing against a predefined panel of drugs (Gemcitabine + Cisplatin,Gemcitabine + Oxaliplatin,Durvalumab + Gemcitabine +...” NCT07351591 ↗ “This study is a single-arm, prospective Phase II clinical trial designed to evaluate the efficacy and safety of Sinibolimab in combination with Lenvatinib as a neoadjuvant...” NCT06848920 ↗ “Medical therapy is the continuation of the immune-based combo for mRCC including one of the available options among axitinib + pembrolizumab or cabozantinib + nivolumab or...” NCT06903312 ↗ “Eligible participants will receive QL1706 at 5.0 mg/kg intravenously every 3 weeks, lenvatinib at 8 mg orally once daily every 3 weeks, oxaliplatin at 85 mg/m², and gemcitabine...” NCT06892925 ↗ “combinations such as atezolizumab plus bevacizumab, tremelimumab plus durvalumab, or monotherapies such as lenvatinib, sorafenib, tislelizumab, durvalumab, or pembrolizumab, at...” NCT06841172 ↗ “The first-line targeted-immunotherapy regimens consisted of tislelizumab combined with one of the first-line evidence-based tyrosine kinase inhibitors (TKIs), including...” NCT07463248 ↗ “Lenvatinib (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) was given orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity,...” NCT05098847 ↗ “TKI (Sorafenib 400mg, bid, po or Lenvatinib 8mg, qd, po if bodyweight less than 60 kg,12mg, qd, po if bodyweight more than 60kg or Donafenib：200mg, bid, po) +...” NCT06041490 ↗ |
| Known as | E-7080 MESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1289601 ↗ |
| Known as | E7080 | “UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone” NCT03139747 ↗8“Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)” NCT02953743 ↗ “A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China” NCT02966093 ↗ |
| Known as | ER-203492-00 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1289601 ↗ |
| Known as | Kisplyx | ChEMBL registry synonym — accepted as the source's own label CHEMBL1289601 ↗ |
| Known as | Len | “Patients in the neoadjuvant therapy group received Lenvatinib before surgery(Len was started before HAIC treatment, discontinued during HAIC treatment, and discontinued...” NCT06420440 ↗5“Patients with advanced intrahepatic cholangiocarcinoma who was initially evaluated unsuitable for the radical therapy and received combined DEB-TACE plus lenvatinib (Len) and...” NCT06192784 ↗ “A phase 3, multinational, randomized, non-inferiority trial (REFLECT) compared the efficacy and safety of lenvatinib (LEN) and sorafenib (SOR) in patients with unresectable...” PMID 31720835 ↗ Nov 2019 “After enrollment, patients will immediately begin treatment with Lenvatinib (Len) and Pucotenlimab (Puco).” NCT06524466 ↗ “received combined HAIC plus lenvatinib (Len) and pucotenlimab” NCT06192797 ↗ “Lenvatinib (LEN) is a first-line therapy” PMID 35921605 ↗ Aug 2022 |
| Known as | Lenvanib | “Lenvanib (Lenvatinib)” NCT07683949 ↗ |
| Known as | Lenvatinib (Lenvima, Eisai China) | “Lenvatinib (Lenvima, Eisai China)” NCT03895970 ↗ |
| Known as | Lenvatinib mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1289601 ↗ |
| Known as | Lenvatinib mesylate | “lenvatinib mesylate capsule, 12 mg (body weight ≥ 60 kg) or 8 mg (body weight \< 60 kg), oral once a day” NCT04273100 ↗3“Lenvatinib mesylate capsule, 8mg (body weight ≤60kg) or 12mg (body weight \>60kg), orally, once daily.” NCT05617859 ↗ “Drug: Lenvatinib Mesylate” NCT02973997 ↗ |
| Known as | Lenvatinib mesylate (USAN) | “Lenvatinib mesylate (USAN)” NCT07571551 ↗ |
| Known as | Lenvatinib methanesulfonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1289601 ↗ |
| Known as | LENVIMA | “Lenvatinib (Lenvima, Eisai China) is a novel angiogenesis inhibitor which targets vascular endothelial growth factor 1-3, fibroblast growth factor receptor 1-4,...” NCT04444193 ↗3“Participants will receive approximately six, 28-day cycles of lenvatinib (LENVIMA®, Eisai Inc., Woodcliff Lake, NJ).” NCT05171335 ↗ “Lenvatinib 4 MG Oral Capsule [Lenvima]” NCT05056337 ↗ “Lenvima” NCT04008797 ↗ |
| Known as | Lenvima/MK-7902/E7080 (Lenvatinib) | “Lenvima/MK-7902/E7080 (Lenvatinib)” NCT05832827 ↗ |
| Known as | Ramvatinib mesylate | “Ramvatinib mesylate is a class of multi-target receptor tyrosine kinase inhibitors, which can block a series of regulatory factors including VEGFR1-3, KIT and RET in tumor...” NCT04909866 ↗ |
| Action | Inhibit | “Lenvatinib (E7080), an oral multi-kinase inhibitor, has inhibitory action on tumor cell proliferation and tumor angiogenesis in preclinical models.” PMID 25047123 ↗ Jul 2014 |
| Modality | Small molecule | “the multitargeted tyrosine kinase inhibitor, lenvatinib” PMID 32265508 ↗ Apr 2020 |
| Route | Oral | “Oral.” NCT00121680 ↗ |
| Target | KIT | “Lenvatinib is an oral inhibitor of vascular endothelial growth factor receptor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor alpha, RET, and KIT.” PMID 27704266 ↗ Oct 2016 |
| Target | RET | “Lenvatinib is an oral inhibitor of vascular endothelial growth factor receptor 1-3, fibroblast growth factor receptor 1-4, platelet-derived growth factor receptor alpha, RET, and KIT.” PMID 27704266 ↗ Oct 2016 |